Dive into some
exciting news

SeaStar Medical recognizes that key inflammatory messengers can be transformed. See how we're transforming medicine.

Disruptive thinking from a solutions-oriented organization

SeaStar Medical is a privately held, clinical-stage medical therapeutics company headquartered in Denver, Colorado. Our revolutionary Selective Cytopheretic Device (SCD) is in the final stages of clinical testing with an anticipated launch date in the second half of 2021.

For any media inquiries, please contact patty@pscconsulting.net

Latest News

SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD

Case report published in peer-reviewed journal, Pediatric Nephrology DENVER, CO and TAMPA, FL — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced that SeaStar Medical’s novel Selective Cytopheretic Device (SCD) was successfully used in a pediatric patient with hemophagocytic lymphohistiocytosis (HLH), a dysregulated immune disorder in children associated with Epstein Barr virus (EBV), the virus that causes mononucleosis. In its most severe form, HLH presents with signs and symptoms of hyperinflammation that can progress to

Read more >

SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury

Application follows successful pilot study demonstrating the SCD was safe with probable clinical benefits for pediatric patients DENVER, CO and TAMPA, FL, July 20, 2022  — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced SeaStar Medical has submitted its application to the U.S. Food and Drug Administration (“FDA”) for Humanitarian Device Exemption (HDE) for use of the Selective Cytopheretic Device (SCD) for critically-ill children with acute kidney injury (AKI). The FDA informed SeaStar Medical that

Read more >

SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms

Results published in the Society of Critical Care Management’s journal, Critical Care Explorations DENVER, CO and TAMPA, FL, June 7, 2022 — SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced the publication of results from SeaStar Medical’s pilot SCD 005 clinical study to evaluate the safety and clinical outcomes of extracorporeal immunomodulation treatment with SeaStar Medical’s Selective Cytopheretic Device (SCD) in COVID-19 patients with multiple organ failure in the intensive care unit (ICU). The article,

Read more >

SeaStar Medical Appoints Kevin Chung, MD as Chief Medical Officer

Dr. Chung is a renowned critical care physician, research and thought leader in extracorporeal life support therapies DENVER, CO and TAMPA, FL, May 24, 2022 — SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS).

Read more >

SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients

Designation helps enable accelerated regulatory review of upcoming pivotal clinical trial for treatment in adult patients with acute kidney injury DENVER, CO and TAMPA, FL, May 03, 2022 — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a special purpose acquisition company, today announced that SeaStar Medical’s Selective Cytopheretic Device (SCD) has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The SCD is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils

Read more >

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

SeaStar Medical is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs Transaction to provide SeaStar with access to the capital markets, allowing it to accelerate the development and advancement of its proprietary and innovative immunomodulatory platform for pediatric and adult acute kidney injury (AKI) SeaStar Medical plans to advance other programs for acute and chronic inflammations, including conditions associated with Covid-19 Dow Pension Plans, as existing investors of SeaStar Medical, commit to further participate in the transaction through a PIPE investment The proposed business combination is expected to be completed in the third

Read more >

The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.